Clinical Trial Update: A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial of Granix to disrupt the bone marrow microenvironment in patients with multiple myeloma undergoing autologous transplantation; study terminated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GRANIX (tbo-filgrastim)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2019-01-07